Keyphrases
Acute Myeloid Leukemia
60%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Allogeneic Transplantation
9%
Autologous Transplantation
17%
Azacitidine
16%
B-cell Lymphoma
9%
Chemotherapy
18%
Chronic Lymphocytic Leukemia
9%
Classical Hodgkin Lymphoma
11%
Complete Remission
19%
Conditioning Regimen
10%
Confidence Interval
27%
Cyclophosphamide
9%
Cytarabine
18%
Decitabine
25%
Diffuse Large B-cell Lymphoma (DLBCL)
44%
Follicular Lymphoma
19%
Graft-versus-host Disease (GvHD)
14%
Granulocyte Colony-stimulating Factor (G-CSF)
24%
Hazard Ratio
13%
Hematopoietic Cell Transplantation
11%
Hodgkin Lymphoma
15%
Hypomethylating Agents
9%
Interleukin-15 (IL-15)
11%
Lenalidomide
16%
Leukemia
16%
Leukemia Patients
11%
Lymphoma
15%
Lymphoma Patients
25%
Maintenance Therapy
9%
Mantle Cell Lymphoma
25%
Memory-like
11%
Myeloablative Conditioning
9%
Myelodysplastic Syndrome
36%
Natural Killer Cells
19%
Older Patients
15%
Overall Response Rate
12%
Overall Survival
31%
Phase I Study
12%
Phase II Study
24%
Plerixafor
23%
Progression-free Survival
19%
Reduced-intensity Conditioning
9%
Relapsed Lymphoma
16%
Relapsed or Refractory
35%
Relapsed or Refractory Acute Myeloid Leukemia
14%
Rituximab
27%
Stem Cell Mobilization
11%
Stem Cells
12%
Unrelated Donor
11%
Medicine and Dentistry
Acute Myeloid Leukemia
49%
Allogeneic Stem Cell Transplantation
11%
Allograft
7%
Autologous Stem Cell Transplantation
12%
Autotransplantation
10%
Azacitidine
14%
Bendamustine
8%
Cell Therapy
9%
Cell Transplantation
46%
Chemokine Receptor CXCR4 Antagonist
8%
Chemotherapy
20%
Classical Hodgkin Lymphoma
14%
Clinical Trial
9%
Conditioning
7%
Cytarabine
10%
Decitabine
17%
Diffuse Large B-Cell Lymphoma
35%
Disease
11%
Follicular Lymphoma
11%
Graft Versus Host Reaction
9%
Granulocyte Colony Stimulating Factor
13%
Hazard Ratio
10%
Hematopoietic Cell
54%
Hematopoietic Stem Cell Transplantation
11%
Hodgkin's Lymphoma
18%
Hypomethylating Agent
7%
Interleukin 15
6%
Lenalidomide
11%
Leukemia
13%
Lymphoma Cell
6%
Maintenance Therapy
6%
Malignant Neoplasm
9%
Mantle Cell Lymphoma
21%
Myeloablative Conditioning
7%
Myelodysplastic Syndrome
20%
Natural Killer Cell
18%
Neoplasm
19%
Non-Hodgkin Lymphoma
7%
Overall Survival
33%
Plerixafor
21%
Polyethylene Terephthalate
7%
Positron Emission Tomography-Computed Tomography
8%
Progression Free Survival
15%
Reduced Intensity Conditioning
7%
Rituximab
21%
Stem Cell
11%
Stem Cell Mobilization
8%
Stem Cell Transplant
12%
T Cell
7%
Transplantation
34%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
48%
Adverse Event
6%
Azacitidine
17%
Belinostat
8%
Bendamustine
9%
Chemokine Receptor CXCR4 Antagonist
5%
Chemotherapy
9%
Chronic Lymphatic Leukemia
8%
Classical Hodgkin Lymphoma
5%
Clinical Trial
6%
Clofarabine
5%
Cyclophosphamide
8%
Cytarabine
15%
Decitabine
23%
Diffuse Large B Cell Lymphoma
19%
Disease
9%
Fludarabine
6%
Follicular Lymphoma
10%
Graft Versus Host Reaction
6%
Granulocyte Colony Stimulating Factor
13%
Lenalidomide
16%
Mantle Cell Lymphoma
10%
Maximum Tolerated Dose
7%
Multiple Myeloma
6%
Myelodysplastic Syndrome
35%
Neoplasm
9%
Nonhodgkin Lymphoma
6%
Overall Survival
15%
Peripheral T Cell Lymphoma
5%
Pharmacokinetics
6%
Plerixafor
19%
Polyethylene Terephthalate
8%
Progression Free Survival
14%
Remission
23%
Rituximab
18%
Tolerability
5%